Release Date: December 21, 2011
National Cancer Institute (NCI)
This Notice is designed to help potential applicants identify appropriate Funding Opportunity Announcements (FOAs) pertaining to the program Innovative Molecular Analysis Technologies (IMAT) for Cancer that has been reissued by the National Cancer Institute (NCI). The goal of the IMAT Program is to develop tools and methods that enable cancer researchers to make new discoveries, enhance our understanding of cancer etiology and proliferation, improve detection capabilities, develop diagnostic methods and treatment strategies, conduct large population studies, address and reduce disparities in clinical care, and assist in clinical decision-making.
The IMAT Program supports research in the following areas
(and will comprise four separate FOAs):
The complete matrix of four IMAT FOAs is provided in the Table below along with basic requirements and total amounts of set-aside funds for each theme for Fiscal Years 2012 and 2013.
Table. The matrix of IMAT RFAs and an outline of their characteristics.
|
Theme and Total Set-Aside Funds |
Innovative Technology Development for Cancer Research $5M |
Validation
of Emerging Technologies in Cancer Research |
Innovative and Emerging Technologies in Biospecimen Science $1.5M |
Project Type and General Requirements |
||||
Exploratory-pilot |
RFA-CA-12-002 |
RFA-CA-12-004 |
||
Developmental/ validation in a biological context Required: Feasibility data |
RFA-CA-12-003 |
RFA-CA-12-005 |
a) Even though preliminary data
are not necessary, the applicants must
demonstrate the innovative nature of the particular technology or
approach proposed for development.
b) Quantitative milestones for each specific aim
must be provided as a way of determining during the project and at its
completion whether an applicant has successfully reached the specified goal. Milestones should be clearly stated
as numerical quantitative specifications for relevant
measures/properties.
Please note that for comprehensive information on all of the submission requirements (including critical aspects of responsiveness), it is essential that every applicant read the full individual IMAT FOA before preparing and submitting an application in response to the selected FOA.
Please direct all inquiries to:
Tony Dickherber, Ph.D.
Program Director
Center for Strategic Scientific Initiatives, Office of the
Director
National Cancer Institute
31 Center Drive, Room 10A-33
Bethesda, MD 20892
Tel: (301) 827-4374
Email: dickherberaj@mail.nih.gov
http://innovation.cancer.gov